Veralto Enters Agreement to Acquire GlobalVision

Veralto announced it has entered into a definitive agreement to acquire GlobalVision, subject to customary closing conditions. GlobalVision, headquartered in Montreal, leverages its core proprietary deterministic technology with AI-augmented functionality to help pharmaceutical and consumer packaged goods customers accelerate their speed to market and meet critical quality and packaging compliance regulations, verifying that packaging content remains accurate and compliant at every critical hand-off. Since 2023, GlobalVision has grown sales at a compound annual growth rate of approximately 19% with expected future sales growth in the mid-teens. In 2026, GlobalVision is expected to deliver approximately $25 million in sales, with approximately 85% on a recurring basis. On a standalone basis, GlobalVision's 2026 adjusted EBITDA margin is expected to be approximately 30%, excluding deal related costs. The acquisition is expected to be neutral to Veralto's adjusted EPS in 2026 and accretive to adjusted EPS in 2027. The purchase price is approximately 15x estimated adjusted EBITDA of $13 million, which is comprised of 2026 estimated standalone adjusted EBITDA plus cost synergies expected to be achieved by the end of year two. By year three, the return on invested capital is expected to exceed the Company's weighted average cost of capital.